Piramal Pharma Solutions expands in vitro biology capabilities
This new expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
Mumbai: Piramal Pharma Limited's Pharma Solutions (PPS) business, a Contract Research, Development and Manufacturing Organization (CDMO), announced that the company has made a multi-million dollar investment to create a world-class high-throughput screening facility that will augment the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.
This new expansion, which is expected to go live in Q3 2022, will significantly add to the primary and secondary screening capabilities of compounds prepared at the Ahmedabad site.
The benefits of this new investment will be seen in an improved experience for PPS discovery services customers. With integrated chemistry and biology services now available from a single site, we anticipate significant improvements to drug discovery cycle times. In addition, new personnel with experience in biology services are being added to the site team, complementing the existing technical and operational expertise.
Also Read: Piramal board approves scheme for pharma business demerger
The new high-throughput screening technology enables PPS to evaluate and screen 1000 compounds per week using various assay platform technologies such as Fluorescent Imaging Plate Reader (FLIPR), TR-FRET/HTRF, Fluorescence Polarization (FP), absorbance, Luminescence/ Electrochemiluminescence (ECL), Alpha Screen, Lantha Screen, Flow Cytometry, and high content imaging. These platforms will be applicable to a variety of targets (e.g., G-protein-coupled receptors (GPCRs) and kinase-targeted therapies).
Peter DeYoung, Chief Executive Officer, Piramal Pharma Solutions, said, "Assisting customers in the discovery process is synergistic with our efforts to be a patient-centric CDMO. With this investment, we are enhancing our discovery platform by adding new in vitro biology services to our existing capabilities, making us a more integrated partner."
Also Read: Piramal Pharma picks up 27.78 per cent stake in Yapan Bio for Rs 102 crore
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.